Terms: = Bone cancer AND MSH6, GTBP, P52701, 2956, ENSG00000116062, HSAP, HNPCC5
27 results:
1. Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study.
Ercan AB; Aronson M; Fernandez NR; Chang Y; Levine A; Liu ZA; Negm L; Edwards M; Bianchi V; Stengs L; Chung J; Al-Battashi A; Reschke A; Lion A; Ahmad A; Lassaletta A; Reddy AT; Al-Darraji AF; Shah AC; Van Damme A; Bendel A; Rashid A; Margol AS; Kelly BL; Pencheva B; Heald B; Lemieux-Anglin B; Crooks B; Koschmann C; Gilpin C; Porter CC; Gass D; Samuel D; Ziegler DS; Blumenthal DT; Kuo DJ; Hamideh D; Basel D; Khuong-Quang DA; Stearns D; Opocher E; Carceller F; Baris Feldman H; Toledano H; Winer I; Scheers I; Fedorakova I; Su JM; Vengoechea J; Sterba J; Knipstein J; Hansford JR; Gonzales-Santos JR; Bhatia K; Bielamowicz KJ; Minhas K; Nichols KE; Cole KA; Penney L; Hjort MA; Sabel M; Gil-da-Costa MJ; Murray MJ; Miller M; Blundell ML; Massimino M; Al-Hussaini M; Al-Jadiry MF; Comito MA; Osborn M; Link MP; Zapotocky M; Ghalibafian M; Shaheen N; Mushtaq N; Waespe N; Hijiya N; Fuentes-Bolanos N; Ahmad O; Chamdine O; Roy P; Pichurin PN; Nyman P; Pearlman R; Auer RC; Sukumaran RK; Kebudi R; Dvir R; Raphael R; Elhasid R; McGee RB; Chami R; Noss R; Tanaka R; Raskin S; Sen S; Lindhorst S; Perreault S; Caspi S; Riaz S; Constantini S; Albert S; Chaleff S; Bielack S; Chiaravalli S; Cramer SL; Roy S; Cahn S; Penna S; Hamid SA; Ghafoor T; Imam U; Larouche V; Magimairajan Issai V; Foulkes WD; Lee YY; Nathan PC; Maruvka YE; Greer MC; Durno C; Shlien A; Ertl-Wagner B; Villani A; Malkin D; Hawkins C; Bouffet E; Das A; Tabori U
Lancet Oncol; 2024 May; 25(5):668-682. PubMed ID: 38552658
[TBL] [Abstract] [Full Text] [Related]
2. Constitutional Mismatch Repair Deficiency Syndrome as a Cause of Numerous Malignancies in a Teenage Patient-A Case Report.
Samborska M; Galli D; Achkar R; Thambyrajah S; Derwich K
J Pediatr Hematol Oncol; 2023 Oct; 45(7):e917-e920. PubMed ID: 37526375
[TBL] [Abstract] [Full Text] [Related]
3. Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors.
Shinojima N; Ozono K; Yamamoto H; Abe S; Sasaki R; Tomita Y; Kai A; Mori R; Yamamoto T; Uekawa K; Matsui H; Nosaka K; Matsuzaki H; Komohara Y; Mikami Y; Mukasa A
Brain Tumor Pathol; 2023 Jul; 40(3):185-190. PubMed ID: 37086325
[TBL] [Abstract] [Full Text] [Related]
4. Expression of Programmed Cell Death-L1 (PD-L1) Protein and Mismatch Repair Mutations in Orbital Tumours-a Pilot Study.
AlSemari MA; Strianese D; Abu Safieh L; Al Hussain H; Abedalthagafi M; Edward DP
Eur J Ophthalmol; 2022 Sep; 32(5):3097-3102. PubMed ID: 34931541
[TBL] [Abstract] [Full Text] [Related]
5. Mismatch repair deficiency is rare in bone and soft tissue tumors.
Lam SW; Kostine M; de Miranda NFCC; Schöffski P; Lee CJ; Morreau H; Bovée JVMG
Histopathology; 2021 Oct; 79(4):509-520. PubMed ID: 33825202
[TBL] [Abstract] [Full Text] [Related]
6. Immunohistochemical Expression Pattern of MLH1, MSH2, msh6, and PMS2 in Tumor Specimen of Iranian Gastric Carcinoma Patients.
Salari S; Ghadyani M; Karimi M; Mortezazadeh M; Vahedifard F
J Gastrointest Cancer; 2022 Mar; 53(1):192-196. PubMed ID: 33411254
[TBL] [Abstract] [Full Text] [Related]
7. Germline and somatic DNA repair gene alterations in prostate cancer.
Dall'Era MA; McPherson JD; Gao AC; DeVere White RW; Gregg JP; Lara PN
Cancer; 2020 Jul; 126(13):2980-2985. PubMed ID: 32315455
[TBL] [Abstract] [Full Text] [Related]
8. Tumour mismatch repair protein loss is associated with advanced stage in oral cavity squamous cell carcinoma.
Vasan K; Satgunaseelan L; Anand S; Asher R; Selinger C; Low TH; Palme CE; Clark JR; Gupta R
Pathology; 2019 Dec; 51(7):688-695. PubMed ID: 31630878
[TBL] [Abstract] [Full Text] [Related]
9. Recurrent Undifferentiated Carcinoma of the Sella in a Patient with Lynch Syndrome.
Voisin MR; Almeida JP; Perez-Ordonez B; Zadeh G
World Neurosurg; 2019 Dec; 132():219-222. PubMed ID: 31491579
[TBL] [Abstract] [Full Text] [Related]
10. Inhibitory effect of msh6 gene silencing in combination with cisplatin on cell proliferation of human osteosarcoma cell line MG63.
Liu HC; Zeng J; Zhang B; Liu XQ; Dai M
J Cell Physiol; 2019 Jun; 234(6):9358-9369. PubMed ID: 30456894
[TBL] [Abstract] [Full Text] [Related]
11. Analysis of Sebaceous Neoplasms for DNA Mismatch Repair Proteins in Muir-Torre Syndrome.
Pollinger TH; Kieliszak CR; Logemann N; Gratrix ML
Skinmed; 2017; 15(4):259-264. PubMed ID: 28859734
[TBL] [Abstract] [Full Text] [Related]
12. CSE1L interaction with msh6 promotes osteosarcoma progression and predicts poor patient survival.
Cheng DD; Lin HC; Li SJ; Yao M; Yang QC; Fan CY
Sci Rep; 2017 Apr; 7():46238. PubMed ID: 28387323
[TBL] [Abstract] [Full Text] [Related]
13. [Muir-Torre syndrome and Turcot syndrome].
Velter C; Caussade P; Fricker JP; Cribier B
Ann Dermatol Venereol; 2017; 144(8-9):525-529. PubMed ID: 28256262
[TBL] [Abstract] [Full Text] [Related]
14. LuCaP Prostate cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating cancer Therapeutics.
Nguyen HM; Vessella RL; Morrissey C; Brown LG; Coleman IM; Higano CS; Mostaghel EA; Zhang X; True LD; Lam HM; Roudier M; Lange PH; Nelson PS; Corey E
Prostate; 2017 May; 77(6):654-671. PubMed ID: 28156002
[TBL] [Abstract] [Full Text] [Related]
15. MSI detection and its pitfalls in CMMRD syndrome in a family with a bi-allelic MLH1 mutation.
Nguyen A; Bougeard G; Koob M; Chenard MP; Schneider A; Maugard C; Entz-Werle N
Fam Cancer; 2016 Oct; 15(4):571-7. PubMed ID: 27017609
[TBL] [Abstract] [Full Text] [Related]
16. An infant with MLH3 variants, FOXG1-duplication and multiple, benign cranial and spinal tumors: A clinical exome sequencing study.
Kansal R; Li X; Shen J; Samuel D; Laningham F; Lee H; Panigrahi GB; Shuen A; Kantarci S; Dorrani N; Reiss J; Shintaku P; Deignan JL; Strom SP; Pearson CE; Vilain E; Grody WW
Genes Chromosomes Cancer; 2016 Feb; 55(2):131-42. PubMed ID: 26542077
[TBL] [Abstract] [Full Text] [Related]
17. Target gene mutational pattern in Lynch syndrome colorectal carcinomas according to tumour location and germline mutation.
Pinheiro M; Pinto C; Peixoto A; Veiga I; Lopes P; Henrique R; Baldaia H; Carneiro F; Seruca R; Tomlinson I; Kovac M; Heinimann K; Teixeira MR
Br J Cancer; 2015 Aug; 113(4):686-92. PubMed ID: 26247575
[TBL] [Abstract] [Full Text] [Related]
18. The Mendelian colorectal cancer syndromes.
Tomlinson I
Ann Clin Biochem; 2015 Nov; 52(Pt 6):690-2. PubMed ID: 26169059
[TBL] [Abstract] [Full Text] [Related]
19. NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair.
Bone KM; Wang P; Wu F; Wu C; Li L; Bacani JT; Andrew SE; Lai R
Blood Cancer J; 2015 May; 5(5):e311. PubMed ID: 25978431
[TBL] [Abstract] [Full Text] [Related]
20. Expression of MSH2 and msh6 on a tissue microarray in patients with osteosarcoma.
Jentzsch T; Robl B; Husmann M; Bode-Lesniewska B; Fuchs B
Anticancer Res; 2014 Dec; 34(12):6961-72. PubMed ID: 25503122
[TBL] [Abstract] [Full Text] [Related]
[Next]
